Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494987 · ClinicalTrials.gov registry record · Phase 3
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 431
- Enrollment target
NCT01494987: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT01494987 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 431 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494987, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 431 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable sulfonylurea or metformin therapy in addition to diet and exercise.
Primary Outcome
The average (mean) change from baseline in HbA1c at Week 24 was analyzed.
Interventions
- DRUG Placebo
- BEHAVIORAL Exercise
- BEHAVIORAL Diet
- DRUG Ranolazine
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 431 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT01494987 record still lists
NCT01494987 is an interventional study that assigns participants to a tested intervention. The registered 431 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01494987 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01494987 about?
NCT01494987 is a clinical study titled "Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus". This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable sulfonyl...
What is the current status of trial NCT01494987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 431 participants. The study started on 2012-01. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01494987?
The interventions under investigation include: Placebo (DRUG), Exercise (BEHAVIORAL), Diet (BEHAVIORAL), Ranolazine (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT01494987?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01494987's enrollment target sits among peer trials
431 877th of 2000 higher than 1,124 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05128890 · 431 participants
Evaluation of Resection Techniques for Pancreatic Tumors
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia